ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer
CHICAGO — First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09 trial. In the phase III study after a median of follow-up of 29 months, patients randomized to T-DXd plus pertuzumab had a median PFS by blinded independent central review […]
Trastuzumab Deruxtecan Ushers in New Treatment Era for HER2-Low Breast Cancer
CHICAGO — Patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan (Enhertu) achieved significant improvements in survival compared with those treated with chemotherapy alone, according to results from the DESTINY-Breast04 Trial. In the phase III international study, among a population of 494 patients with both HR-positive disease (88.7%) and HR-negative disease (11.3%), the risk […]